Cover Image
Market Research Report

Global Anti-Malarial Medicines Market 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 711705
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Anti-Malarial Medicines Market 2020-2024
Published: March 27, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the anti-malarial medicines market and it is poised to grow by $ 310.75 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period. Our reports on anti-malarial medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the strong funding to eradicate malaria, growing incidence of malaria, and robust pipeline and recent drug approvals. In addition, strong funding to eradicate malaria is anticipated to boost the growth of the market as well.

The anti-malarial medicines market analysis include product segments and geographic landscapes.

Technavio's ‘anti-malarial medicines market ’ is segmented as below:

By Product:

  • Artemisinin compounds
  • Quinolines and related compounds
  • Other compounds

By Geographic Landscape:

  • APAC
  • Europe
  • MEA
  • North America
  • South America

This study identifies enhanced POC diagnostics and biomarkers for malaria as one of the prime reasons driving the anti-malarial medicines market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our anti-malarial medicines market covers the following areas:

  • Anti-malarial Medicines Market sizing
  • Anti-malarial Medicines Market forecast
  • Anti-malarial Medicines Market industry analysis

Technavio's ‘robust vendor analysis ’ is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-malarial medicines market vendors that include AstraZeneca Plc, Bayer AG, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd.. Also, the anti-malarial medicines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR43201

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Artemisinin compounds - Market size and forecast 2019-2024
  • Quinolines and related compounds - Market size and forecast 2019-2024
  • Other compounds - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • APAC - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Parent market
  • 9.Market characteristics
  • 10.Offerings of vendors included in the market definition
  • 11.Market segments
  • 12.Global - Market size and forecast 2019 - 2024 ($ million)
  • 13.Global market: Year-over-year growth 2019 - 2024 (%)
  • 14.Five forces analysis 2019 & 2024
  • 15.Bargaining power of buyers
  • 16.Bargaining power of suppliers
  • 17.Threat of new entrants
  • 18.Threat of substitutes
  • 19.Threat of rivalry
  • 20.Market condition - Five forces 2019
  • 21.Product - Market share 2019-2024 (%)
  • 22.Comparison by Product
  • 23.Artemisinin compounds - Market size and forecast 2019-2024 ($ million)
  • 24.Artemisinin compounds - Year-over-year growth 2019-2024 (%)
  • 25.Quinolines and related compounds - Market size and forecast 2019-2024 ($ million)
  • 26.Quinolines and related compounds - Year-over-year growth 2019-2024 (%)
  • 27.Other compounds - Market size and forecast 2019-2024 ($ million)
  • 28.Other compounds - Year-over-year growth 2019-2024 (%)
  • 29.Market opportunity by Product
  • 30.Customer landscape
  • 31.Market share by geography 2019-2024 (%)
  • 32.Geographic comparison
  • 33.APAC - Market size and forecast 2019-2024 ($ million)
  • 34.APAC - Year-over-year growth 2019-2024 (%)
  • 35.MEA - Market size and forecast 2019-2024 ($ million)
  • 36.MEA - Year-over-year growth 2019-2024 (%)
  • 37.South America - Market size and forecast 2019-2024 ($ million)
  • 38.South America - Year-over-year growth 2019-2024 (%)
  • 39.Europe - Market size and forecast 2019-2024 ($ million)
  • 40.Europe - Year-over-year growth 2019-2024 (%)
  • 41.North America - Market size and forecast 2019-2024 ($ million)
  • 42.North America - Year-over-year growth 2019-2024 (%)
  • 43.Key leading countries
  • 44.Market opportunity by geography ($ million)
  • 45.Impact of drivers and challenges
  • 46.Vendor landscape
  • 47.Landscape disruption
  • 48.Industry risks
  • 49.Vendors covered
  • 50.Market positioning of vendors
  • 51.AstraZeneca Plc - Overview
  • 52.AstraZeneca Plc - Business segments
  • 53.AstraZeneca Plc - Key offerings
  • 54.AstraZeneca Plc - Key customers
  • 55.AstraZeneca Plc - Segment focus
  • 56.Bayer AG - Overview
  • 57.Bayer AG - Business segments
  • 58.Bayer AG - Key offerings
  • 59.Bayer AG - Key customers
  • 60.Bayer AG - Segment focus
  • 61.Cipla Inc. - Overview
  • 62.Cipla Inc. - Business segments
  • 63.Cipla Inc. - Key offerings
  • 64.Cipla Inc. - Key customers
  • 65.Cipla Inc. - Segment focus
  • 66.F. Hoffmann-La Roche Ltd. - Overview
  • 67.F. Hoffmann-La Roche Ltd. - Business segments
  • 68.F. Hoffmann-La Roche Ltd. - Key offerings
  • 69.F. Hoffmann-La Roche Ltd. - Key customers
  • 70.F. Hoffmann-La Roche Ltd. - Segment focus
  • 71.GlaxoSmithKline Plc - Overview
  • 72.GlaxoSmithKline Plc - Business segments
  • 73.GlaxoSmithKline Plc - Key offerings
  • 74.GlaxoSmithKline Plc - Key customers
  • 75.GlaxoSmithKline Plc - Segment focus
  • 76.Mylan NV - Overview
  • 77.Mylan NV - Business segments
  • 78.Mylan NV - Key offerings
  • 79.Mylan NV - Key customers
  • 80.Mylan NV - Segment focus
  • 81.Novartis AG - Overview
  • 82.Novartis AG - Business segments
  • 83.Novartis AG - Key offerings
  • 84.Novartis AG - Key customers
  • 85.Novartis AG - Segment focus
  • 86.Pfizer Inc. - Overview
  • 87.Pfizer Inc. - Business segments
  • 88.Pfizer Inc. - Key offerings
  • 89.Pfizer Inc. - Key customers
  • 90.Pfizer Inc. - Segment focus
  • 91.Sanofi - Overview
  • 92.Sanofi - Business segments
  • 93.Sanofi - Key offerings
  • 94.Sanofi - Key customers
  • 95.Sanofi - Segment focus
  • 96.Sun Pharmaceutical Industries Ltd. - Overview
  • 97.Sun Pharmaceutical Industries Ltd. - Business segments
  • 98.Sun Pharmaceutical Industries Ltd. - Key offerings
  • 99.Sun Pharmaceutical Industries Ltd. - Key customers
  • 100.Sun Pharmaceutical Industries Ltd. - Segment focus
  • 101.Currency conversion rates for US$
  • 102.Research Methodology
  • 103.Validation techniques employed for market sizing
  • 104.Information sources
  • 105.List of abbreviations
Back to Top